Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral magnesium supplementation and insulin sensitivity in insulin-treated type 2 diabetes mellitus
2021-001243-27Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of magnesium gluconate in type 2 diabetes mellitus (T2DM) and hypomagnesaemia, sponsored by Radboudumc. Primary endpoints: Change in insulin sensitivity and Change in insulin dose requirements. Started Sep 2021; status: completed.
02
Drugs
magnesium gluconate
03
Conditions
type 2 diabetes mellitus (T2DM)hypomagnesaemia
Beyond the preview
Go deeper on 2021-001243-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001243-27.